Status:
COMPLETED
Temocillin in ESBL-Enterobacteriaceae Infections
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Infectious Disease
Eligibility:
All Genders
18-99 years
Brief Summary
Because of the increasing incidence of infections with multi-drug resistant enterobacteriaceae, we need alternative treatments to spare carbapenems. Temocillin could be an interesting option but its p...
Detailed Description
We will retrospectively include every patient who received at least 24 hours of temocillin for the treatment of an extended-spectrum beta-lactamase Enterobacteriaceae (ESBL-E) infection from January t...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- All patients who received at least 24 hours of temocillin for the treatment of ESBL enterobacteriaceae infection / colonization from January to December 2016 in the university hospitals of Tenon and Pitié Salpêtrière. All indications, including excluding recommendations.
- Informed and not opposed to the use of their data
Exclusion
- Patient \< 18 years
- Pregnancy
- Refusal to participate
- Multi-resistant bacterial infection not treated with temocillin
- Temocillin resistant bacteria
Key Trial Info
Start Date :
October 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 24 2022
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT05413772
Start Date
October 20 2022
End Date
November 24 2022
Last Update
February 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié-Salpêtrière University Hospital
Paris, France, 75013
2
Tenon University Hospital
Paris, France, 75020